Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Royalty Pharma PLC (RPRX)
NASDAQ:RPRX
Earnings Data
Report Date
May 07, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
1.07Last Year’s EPS
0.98Same Quarter Last Year
Strong Buy
Based on 3 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 11, 2025
|% Change Since: 5.08%
|Next Earnings Date:May 07, 2025
Earnings Call Sentiment|Positive
The earnings call for Royalty Pharma presents a positive outlook with significant portfolio growth, strategic FDA approvals, strong capital deployment, and the internalization transaction poised to deliver substantial future savings. Despite some challenges, such as the impact of onetime Biohaven payments and potential interest expense increases, the company's robust financial performance and strategic initiatives suggest a strong position for future growth.Company Guidance
During the Royalty Pharma Fourth Quarter Earnings Conference, the guidance for 2025 was outlined, highlighting anticipated Portfolio Receipts of $2.9 billion to $3.05 billion, reflecting a growth rate of approximately 4% to 9% from 2024's Portfolio Receipts of $2.8 billion. The company noted that its 13% growth in Royalty Receipts for 2024 significantly exceeded the initial guidance of 5% to 9%. Looking ahead, the company plans to allocate $2 billion towards share repurchases in 2025 as part of a new $3 billion share repurchase plan. Additionally, operational costs are expected to be around 10% of Portfolio Receipts, with potential cash savings of over $100 million anticipated in 2026 following the internalization of the company's management structure. This internalization is expected to yield cumulative savings exceeding $1.6 billion over the next decade.Record Portfolio Receipts and Growth
Royalty Pharma delivered Portfolio Receipts of $2.8 billion for 2024, representing a growth of 13%, which significantly exceeded their initial guidance of 5% to 9%.
FDA Approvals and Strategic Portfolio Additions
The company saw FDA approvals for Voranigo for brain cancer, Cobenfy for schizophrenia, and Tremfya for ulcerative colitis, along with the acceptance of the NDA for Cytokinetics' aficamten for obstructive hypertrophic cardiomyopathy.
Strong Capital Deployment
Royalty Pharma deployed $2.8 billion to broaden its portfolio and $230 million on share repurchases. They announced a new $3 billion share repurchase plan, intending to repurchase $2 billion in 2025.
Internalization Transaction
Announced a transformative acquisition of their external manager to become an integrated company, expected to yield strategic and financial benefits, including savings of over $100 million in 2026.
Synthetic Royalties Growth
Achieved a record year for synthetic royalty transactions of $925 million in 2024, more than doubling since 2020.
Strong Cash Flow Generation
Royalty Receipts grew by 13% for the year, and the company maintained a high cash conversion rate with a portfolio cash flow of $2.45 billion at a margin of just under 88%.
Resilient Financial Capacity
Ended the year with $929 million in cash and equivalents, with an investment-grade debt outstanding of $7.8 billion and a leverage ratio of around 3x total debt to EBITDA.
---
RPRX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
RPRX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 11, 2025 | $31.72 | $32.25 | +1.67% |
| Nov 06, 2024 | $27.31 | $26.42 | -3.26% |
| Aug 08, 2024 | $26.82 | $25.74 | -4.03% |
| May 09, 2024 | $27.34 | $27.32 | -0.07% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Royalty Pharma PLC (RPRX) report earnings?
Royalty Pharma PLC (RPRX) is schdueled to report earning on May 07, 2025, TBA Not Confirmed.
What is Royalty Pharma PLC (RPRX) earnings time?
Royalty Pharma PLC (RPRX) earnings time is at May 07, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is RPRX EPS forecast?
RPRX EPS forecast for the fiscal quarter 2025 (Q1) is 1.07.
---